Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Tax Provisions (2020 - 2025)

Mirum Pharmaceuticals has reported Tax Provisions over the past 6 years, most recently at $767000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $767000.0 for Q4 2025, up 233.16% from a year ago — trailing twelve months through Dec 2025 was $1.9 million (up 87.96% YoY), and the annual figure for FY2025 was $1.9 million, up 87.96%.
  • Tax Provisions for Q4 2025 was $767000.0 at Mirum Pharmaceuticals, up from -$262000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for MIRM hit a ceiling of $1.0 million in Q1 2025 and a floor of -$6.6 million in Q2 2022.
  • Median Tax Provisions over the past 5 years was $170500.0 (2022), compared with a mean of -$120600.0.
  • Biggest five-year swings in Tax Provisions: crashed 59827.27% in 2022 and later surged 1815.38% in 2023.
  • Mirum Pharmaceuticals' Tax Provisions stood at $12000.0 in 2021, then surged by 1066.67% to $140000.0 in 2022, then soared by 60.71% to $225000.0 in 2023, then tumbled by 356.0% to -$576000.0 in 2024, then skyrocketed by 233.16% to $767000.0 in 2025.
  • The last three reported values for Tax Provisions were $767000.0 (Q4 2025), -$262000.0 (Q3 2025), and $402000.0 (Q2 2025) per Business Quant data.